Patents Assigned to Sigma-Tau
  • COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY
    Publication number: 20130005670
    Abstract: It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.
    Type: Application
    Filed: February 7, 2011
    Publication date: January 3, 2013
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Mohamed Ashraf Virmani, Aleardo Koverech
  • Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
    Patent number: 8343979
    Abstract: Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 1, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Aleardo Koverech, Andrea Lenzi
  • Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
    Patent number: 8337828
    Abstract: It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 25, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luigina Romani, Francesco Bistoni, Enrico Garaci
  • Anti-EpCAM antibody and uses thereof
    Patent number: 8318911
    Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumor selectivity.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: November 27, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Anna Maria Anastasi, Fiorella Petronzelli, Rita De Santis, Saverio Alberti
  • Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere
    Patent number: 8292869
    Abstract: A container for a vial of radiopharmaceutical, made of polymethyl methacrylate consists of a receptacle, with a cavity capable of containing the vial of radiopharmaceutical, and of a lid screwed onto the receptacle for closing the container, said lid presenting a central through-hole. A set, in combination with this container with the vial of radiopharmaceutical, consisting of a bottle of saline solution and two infusion catheters, enhances the radioprotection during the infusion of a radiopharmaceutical in an infusion operation.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: October 23, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Giovanni Paganelli, Marco Chinol
  • NON-NATURAL MACROCYCLIC AMIDE HDAC6 INHIBITOR COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20120258993
    Abstract: The present invention relates to novel amide compounds of formula I, and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC6 is responsive, and the pharmaceutical composition containing such compounds.
    Type: Application
    Filed: September 21, 2010
    Publication date: October 11, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Stephan Hanessian, Luciana Auzzas, Andreas Larsson
  • ANTICANCER COMBINATION OF ARTEMISININ-BASED DRUGS AND OTHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20120258181
    Abstract: The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.
    Type: Application
    Filed: December 6, 2010
    Publication date: October 11, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Claudio Pisano, Loredana Vesci
  • CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20120252865
    Abstract: The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.
    Type: Application
    Filed: March 8, 2010
    Publication date: October 4, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Walter Cabri, Patrizia Minetti, Giuseppe Campiani, Stefania Butini
  • Crystalline form II of 7-(dimethoxy-methyl) camptothecin, its use as intermediate and products obtained therefrom
    Patent number: 8269007
    Abstract: This invention relates to a process for preparing a crystalline form of (4S)-11(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3?4?:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing from methanol.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: September 18, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Elena Badaloni, Silvia Armaroli, Giuseppe Marazzi
  • Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
    Patent number: 8268304
    Abstract: It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: September 18, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Paolo Carminati, Marica Sassano, Francesco Bistoni, Luigina Romani, Silvia Bozza
  • Dietary supplement energy-providing to skeletal muscles
    Patent number: 8252309
    Abstract: Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: August 28, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventor: Franco Gaetani
  • TREATMENT OF ONCOLOGICAL DISEASES
    Publication number: 20120208883
    Abstract: The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed.
    Type: Application
    Filed: December 1, 2009
    Publication date: August 16, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
    Inventors: Claudio Cavazza, Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
  • Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
    Patent number: 8222231
    Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: July 17, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Food supplement with a slimming effect
    Patent number: 8207109
    Abstract: A food supplement with a “slimming” effect is disclosed which strengthens the skeletal muscle, protecting the cardio-vascular apparatus of the user, and has as its characterising components propionyl L-carnitine, coenzyme Q10 nicotinamide, riboflavin and pantothenic acid.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: June 26, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventor: Franco Gaetani
  • Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl L-carnitine and chitosan
    Patent number: 8198260
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: June 12, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventor: Claudio Cavazza
  • USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS
    Publication number: 20120093809
    Abstract: The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms.
    Type: Application
    Filed: December 1, 2009
    Publication date: April 19, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Claudio Cavazza, Giulia Tagliafico, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
  • Use of L-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases
    Patent number: 8158679
    Abstract: Use of L-carnitine or a pharmaceutically acceptable salt thereof, for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal oedema.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: April 17, 2012
    Assignee: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Aleardo Koverech, Nicola Pescosolido
  • Stereoselective process and crystalline forms of a camptothecin
    Patent number: 8124769
    Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: February 28, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
  • USE OF ALKANOYL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION
    Publication number: 20120041005
    Abstract: Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine.
    Type: Application
    Filed: October 25, 2011
    Publication date: February 16, 2012
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A
    Inventors: Aleardo Koverech, Andrea Lenzi
  • Stereoselective process and crystalline forms of a camptothecin
    Patent number: 8101758
    Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: January 24, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti